/AURX
AURX Stock - Nuo Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$2.15+0.00%
+$0.00 (+0.00%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+39.5%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AURX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.13 – $2.17
TARGET (TP)$3.00
STOP LOSS$1.98
RISK/REWARD1:5.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-104.09
52W High$3.23
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.37M | $608,525 | $112,250 | N/A | N/A |
| Gross Profit | $1.06M | $482,433 | $93,036 | N/A | N/A |
| Gross Margin | 77.8% | 79.3% | 82.9% | N/A | N/A |
| Operating Income | $-2,457,835 | $-3,168,274 | $-3,320,594 | $-90,670 | $-378,059 |
| Net Income | $-2,323,705 | $-3,171,436 | $-3,025,298 | $-90,670 | $-139,260 |
| Net Margin | -170.2% | -521.2% | -2695.1% | N/A | N/A |
| EPS | $-0.05 | $-0.08 | $-0.08 | $-0.00 | $-0.01 |
Company Overview
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$3
Average Target
↑ 39.5% Upside
Now
$3
Low
$3
Average
$3
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Roth Capital | Initiation | Buy | $3 |
Earnings History & Surprises
AURXBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 15, 2025 | — | $-0.01 | — | — |
Q2 2025 | Jun 4, 2025 | — | $-0.02 | — | — |
Q2 2025 | Apr 1, 2025 | — | $-0.01 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 12, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.02 | — | — |
Q2 2024 | Apr 19, 2024 | — | $-0.02 | — | — |
Q1 2024 | Feb 5, 2024 | — | $-0.02 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.02 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.02 | — | — |
Q2 2023 | Apr 14, 2023 | — | $-0.02 | — | — |
Q4 2022 | Nov 4, 2022 | — | $-0.02 | — | — |
Q4 2022 | Nov 4, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-0.02 | — | — |
Q2 2022 | May 16, 2022 | — | $-0.01 | — | — |
Q2 2022 | Apr 15, 2022 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Frequently Asked Questions about AURX
What is AURX's current stock price?
Nuo Therapeutics, Inc. (AURX) is currently trading at $2.15 per share. The stock has moved +0.00% today.
What is the analyst price target for AURX?
The average analyst price target for AURX is $3.00, based on 1 analyst.
What sector is Nuo Therapeutics, Inc. in?
Nuo Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is AURX's market cap?
Nuo Therapeutics, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does AURX pay dividends?
No, Nuo Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorGGBXF
Green Growth Brands Inc.
$0.00
Mkt Cap: $0.0B
HOFBF
Hofseth BioCare ASA
$0.17
Mkt Cap: $0.1B
IUGNF
Imugene Limited
$0.22
Mkt Cap: $0.1B
KNTPF
Kintor Pharmaceutical Limited
$0.22
Mkt Cap: $0.1B
MSCLF
Satellos Bioscience Inc.
$0.48
Mkt Cap: $0.1B
PBIGF
Paradigm Biopharmaceuticals Limited
$0.23
Mkt Cap: $0.1B
POLBF
Poolbeg Pharma PLC
$0.04
Mkt Cap: $0.0B
RCEL
AVITA Medical, Inc.
$3.46
Mkt Cap: $0.1B
SPHRY
Starpharma Holdings Limited
$2.20
Mkt Cap: $0.1B
VSBC
VitaSpring Biomedical Co. Ltd.
$1.00
Mkt Cap: $0.2B
Explore stocks similar to AURX for comparison